Curanex Pharmaceuticals Inc

Curanex Pharmaceuticals is a developmental-stage pharmaceutical company focused on discovering and developing botanical-derived drugs for inflammatory disease indications. The company's primary asset is Phyto-N, a botanical drug candidate being evaluated across multiple therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. As a pre-commercial entity, Curanex is in the clinical development phase and has not yet generated meaningful product revenues.

The company was incorporated in Nevada and maintains headquarters in Jericho, New York. Originally established in 1996 as Fordman Pharma, the company underwent a name change to Curanex Pharmaceuticals in November 2023. As a developmental-stage biotech firm, specific information regarding employee headcount, detailed revenue streams, and geographic market penetration is not publicly available.